Inclisiran

Drug Profile

Inclisiran

Alternative Names: ALN-60212; ALN-PCSsc; PCSK9si

Latest Information Update: 11 Jan 2017

Price : $50

At a glance

  • Originator Alnylam Pharmaceuticals
  • Developer Alnylam Pharmaceuticals; The Medicines Company
  • Class Amino sugars; Antihyperlipidaemics; Drug conjugates; Small interfering RNA
  • Mechanism of Action PCSK9 protein inhibitors; RNA interference
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase II Hypercholesterolaemia

Most Recent Events

  • 08 Jan 2017 The Medicines Company initiates enrolment in the ORION-2 trial for Hypercholesterolaemia in Netherlands (SC) (NCT02963311)
  • 08 Jan 2017 The Medicines Company initiates enrolment in the ORION-3 trial for Hypercholesterolaemia in USA, Germany, Netherland, Canada and United Kingdom (SC)
  • 15 Nov 2016 Positive interim efficacy and safety data from the phase II ORION-1 trial in Hypercholesterolaemia released by The Medicines Company and Alnylam Pharmaceuticals
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top